Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b study of PP-01 for the mitigation of Cannabis Withdrawal Syndrome

Next Previous
X
Search
Trial Profile

Phase 1b study of PP-01 for the mitigation of Cannabis Withdrawal Syndrome

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gabapentin/nabilone PleoPharma (Primary)
  • Indications Substance-related disorders
  • Focus Adverse reactions; Proof of concept
  • Acronyms CAN-001

    • Most Recent Events

    • 18 Nov 2024 According to PLEOPHARMA, INC media release, company announced the presentation of data from their Phase 1b Pharmacokinetic and Pharmacodynamic study of Cannabis Withdrawal Syndrome ("CWS") in participants with Cannabis Use Disorder ("CUD") at the annual meeting of the American Academy of Addiction Psychiatry (AAAP) in Naples, Fla.
    • 25 Sep 2024 New trial record
    • 19 Sep 2024 According to PLEOPHARMA, INC media release, Ginger Constantine, MD, presented data from this trial at the Life Sciences PA's Life Sciences Future Conference.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top